Clinical trialNCT07705334RecruitingPhase 1Interventional

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

SponsorSHY TherapeuticsEnrollment30Advanced or Metastatic Solid TumorsColon CancerGastric CancerHR+ Breast CancerHepatecellular CarcinomaHormone Refractory Prostate Cancer+5 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors who have progressed on or are intolerant to standard therapies. The study will consist of 2 parts: a dose escalation part (Phase 1a) and a dose expansion part (Phase 1b).

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Honorhealth Research Institute
Scottsdale, Arizona, United States
Justin Moser, MD
Recruiting
Scri at Hca Healthone
Denver, Colorado, United States
Gerald Falchook, MD
Not, yet, recruiting
the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Timothy Yap, MBBS, PhD
Not, yet, recruiting
Next Oncology
San Antonio, Texas, United States
Ildefonso Rodriguez Rivera, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

SHY-ONC6

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Jun 2026
Primary completion: 15 May 2027
Completion: 15 May 2028
Last update posted: 10 Aug 2026
Registered enrollment: 30
Registry id: NCT07705334

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.